JNJ

Johnson & Johnson | Pharmaceuticals
$239.47
Data as of: 2026-04-15 10:16:01
ER: 2026-04-14
AI Execution Plan
Entry
$239.00
Target
$248.00
Stop
$235.00
STRATEGY NOTEBuy
Fundamental Snapshot
Market Cap
491,255M
P/E Ratio
27.19
Beta
0.31
ROE (TTM)
33.8%
Div Yield
2.25%
Next Earnings
2026-04-14
AI News

Johnson & Johnson beat Q1 2026 earnings with sales $24.1B (+9.9% YoY) vs est $23.6B, adj EPS $2.70 vs $2.68 est. Raised FY2026 guidance: EPS $11.30-$11.50, sales ~$100.8B midpoint. Announced 64th consecutive annual dividend increase to $1.34/share quarterly (up 3.1%). Stock dipped initially on conservative sales outlook amid biosimilar pressures.1113

Sentiment
"Mostly positive on X: Earnings beat, revenue growth, dividend hike (64th year) highlighted. Some note premarket weakness despite raises. Analyst PT upgrades e.g. Bernstein $251. Minor negative/old recall mentions.281214"

Investing.com shows Strong Buy overall: MA summary Buy (7 buy/5 sell), Indicators Strong Buy (8 buy/1 neutral/1 sell). RSI(14): 53.2 (Neutral); MACD: 0.23 (Buy); STOCH: 78.95 (Buy); Trading near short-term MAs, above MA20/50. Low volatility, stable trend post-earnings dip.42

3-Month AI Outlook

Bullish. Strong Q1 beat, raised FY guidance supports growth in Innovative Medicine/MedTech. Dividend aristocrat, low beta defensive play. Analyst targets avg ~$240-250+, potential to test 52W highs near $252 amid stable pharma demand.1140

Option Chain
Expiry:
StrikeBidAskIV %VolOITime
$215.00.120.4841.8%1192026-04-15 10:15:11
$227.50.380.6627.1%1192026-04-15 10:15:25
$230.00.610.8625.6%28402026-04-15 10:15:21
$232.50.951.3825.2%30502026-04-15 10:15:15
$235.01.491.9024.1%12492026-04-15 10:15:22
$237.52.292.6823.4%8102026-04-15 10:15:23
$240.03.244.1323.8%16462026-04-15 10:15:22
$242.54.735.4923.7%20212026-04-15 10:15:22
$245.06.377.1123.2%22122026-04-15 10:15:22
$247.56.8410.8925.0%552026-04-15 10:15:13
$250.09.6712.7828.1%1052026-04-15 10:15:11
$252.511.3415.0525.7%1252026-04-15 10:15:24
$255.013.7417.5728.6%2112026-04-15 10:15:11
$257.517.3820.0940.2%591082026-04-15 10:15:24
$260.019.6022.2839.9%85992026-04-15 10:15:19
$262.521.8825.3545.9%90992026-04-15 10:15:10
$265.024.6227.6649.7%53832026-04-15 10:15:11
$267.526.9530.4053.5%53832026-04-15 10:15:11
$270.029.9532.6658.7%58982026-04-15 10:15:17
$275.034.1037.8259.5%53832026-04-15 10:15:11
$280.039.1643.1969.3%67832026-04-15 10:15:11
$285.044.1248.3476.1%82832026-04-15 10:15:11
$290.050.4453.0089.9%651042026-04-15 10:15:11
$295.055.5256.8386.4%661032026-04-15 10:15:11
$300.060.6862.88102.4%651062026-04-15 10:15:11
$310.069.1973.67107.1%631042026-04-15 10:15:11
StrikeBidAskIV %VolOITime
$185.053.1656.7583.2%1072026-04-15 10:15:24
$190.047.1352.4362.5%342026-04-15 10:15:11
$200.038.1142.1767.5%1082026-04-15 10:15:19
$207.530.6633.8536.1%462026-04-15 10:15:15
$220.018.2121.6431.2%852026-04-15 10:15:15
$222.515.4219.7031.2%452026-04-15 10:15:11
$227.510.8514.5225.8%662026-04-15 10:15:11
$230.08.5611.6720.7%51152026-04-15 10:15:19
$232.56.4210.0323.3%5232026-04-15 10:15:13
$235.05.676.7522.2%882026-04-15 10:15:22
$237.54.485.0523.6%1022026-04-15 10:15:22
$240.03.083.6123.1%1242026-04-15 10:15:22
$242.52.032.5123.0%1412026-04-15 10:15:23
$245.01.301.8123.6%33152026-04-15 10:15:17
$247.50.751.0622.9%63342026-04-15 10:15:12
$250.00.370.7022.9%80282026-04-15 10:15:15
$252.50.232.1834.5%15132026-04-15 10:15:12
$255.00.150.2824.4%71132026-04-15 10:15:17
$260.00.070.3029.4%521382026-04-15 10:15:17
Earnings History: JNJ
Johnson & Johnson Reports Strong Q2 2025 Earnings; Increases Annual Forecast
Jul 16, 2025

In the second quarter of 2025, Johnson & Johnson reported revenue of $23.743 billion, a growth of 5.8% compared to the same quarter in 2024. The company's net income was $5.537 billion, reflecting an 18.2% increase, and earnings per share (EPS) was $2.29, up by 18.7% year-over-year. Research and development (R&D) expenses for the quarter amounted to $3.516 billion, slightly higher than the $3.440 billion spent in Q2 2024. The company is expecting significant growth in the second half of the year, with anticipated approvals in key therapeutic areas including oncology and immunology. Johnson & Johnson's MedTech segment saw a 7.3% increase in operational sales, driven primarily by strong performance in cardiovascular and electrophysiology products. In the Innovative Medicine segment, operational sales grew by 4.9%, supported by successful products like DARZALEX and CARVYKTI. The company also announced that it has raised its full-year 2025 guidance, projecting reported sales to be between $93.2 billion and $93.6 billion, reflecting a year-over-year growth of 5.1% to 5.6%. This positive outlook is based on the anticipated success of new product launches and ongoing clinical advancements.

Earnings Release (Confirmed)
Apr 14, 2026

HIGH

About Jason Wheel

Substack Email
Strategy Overview

Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.

Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.

This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.

Connect with Jason